A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to
evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.